DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Status
To expedite the compact prosecution, the Examiner is pursuing the amended claims dated 17 January 2025, in which applicant claims 1-13.
Therefore, claims 1-13 are pending in the application.
Priority
This application was filed 01/17/2025 and is a 371 application of PCT/CN2024/079709 filed on 03/01/2024, which claims benefit to the foreign priority to 202310190961.2 filed on filed 03/02/2023.
Filing of a certified untranslated copy of the 202310190961.2, filed 03/02/2023is acknowledged. MPEP 2304.01(c) states: Should applicant desire to obtain the benefit of foreign priority under 35 U.S.C. 119(a)-(d) prior to declaration of an interference, a certified English translation of the foreign application must be submitted in reply to this action, 37 CFR 41.154(b) and 41.202(e). Failure to provide a certified translation may result in no benefit being accorded for the non-English application.
Thus, the earliest possible priority for the instant application is 03/01/2024.
Information Disclosure Statement
The information disclosure statement (IDS) submitted on 04/18/2025, 10/25/2025 and 05/29/2026 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner, and the signed and initialed PTO Forms 1449 are mailed with this action.
Claim Rejections - 35 USC § 112 (a)
(Written description)
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 1-10 and 12 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim contains subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor, at the time the application was filed, had possession of the claimed invention.
Under the written description guidelines (see MPEP 2163), the Examiner is directed to determine whether one skilled in the art would recognize that the Applicant was in possession of the claimed invention as a whole at the time of filing. The following considerations are critical to this determination.
To satisfy the written description requirement, a patent specification must describe the claimed invention in sufficient detail so that one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention. See, e.g., Moba, B.V. v. Diamond Automation, Inc., 325 F.3d 1306, 1319, 66 USPQ2d 1429, 1438 (Fed. Cir. 2003); Vas-Cath, Inc. v. Mahurkar, 935 F.2d at 1563, 19 USPQ2d at 1116. An original claim may lack written description support when (1) the claim defines the invention in functional language specifying a desired result but the disclosure fails to sufficiently identify how the function is performed or the result is achieved or (2) a broad genus claim is presented but the disclosure only describes a narrow species with no evidence that the genus is contemplated. See Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1349-50 (Fed. Cir. 2010) (en banc). The written description requirement is not necessarily met when the claim language appears in ipsis verbis in the specification. "Even if a claim is supported by the specification, the language of the specification, to the extent possible, must describe the claimed invention so that one skilled in the art can recognize what is claimed. The appearance of mere indistinct words in a specification or a claim, even an original claim, does not necessarily satisfy that requirement." Enzo Biochem, Inc. v. Gen-Probe, Inc., 323 F.3d 956, 968, 63 USPQ2d 1609, 1616 (Fed. Cir. 2002).
Accordingly, to satisfy the written description requirement, the specification must describe the claimed invention in sufficient detail that one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention. Vas-Cath, Inc. v. Mahurkar, 935 F.2d 1555, 1562-63, 19 USPQ2d 1111 (Fed. Cir. 1991). See also MPEP 2163.
REQUIREMENTS TO ESTABLISH ACTUAL REDUCTION TO PRACTICE
"In an interference proceeding, a party seeking to establish an actual reduction to practice must satisfy a two-prong test: (1) the party constructed an embodiment or performed a process that met every element of the interference count, and (2) the embodiment or process operated for its intended purpose." Eaton v. Evans, 204 F.3d 1094, 1097, 53 USPQ2d 1696, 1698 (Fed. Cir. 2000).
The same evidence sufficient for a constructive reduction to practice may be insufficient to establish an actual reduction to practice, which requires a showing of the invention in a physical or tangible form that shows every element of the count. Wetmore v. Quick, 536 F.2d 937, 942, 190 USPQ 223, 227 (CCPA 1976). For an actual reduction to practice, the invention must have been sufficiently tested to demonstrate that it will work for its intended purpose, but it need not be in a commercially satisfactory stage of development. See, e.g., Scott v. Finney, 34 F.3d 1058, 1062, 32 USPQ2d 1115, 1118-19 (Fed. Cir. 1994) (citing numerous cases wherein the character of the testing necessary to support an actual reduction to practice varied with the complexity of the invention and the problem it solved). If a device is so simple, and its purpose and efficacy so obvious, construction alone is sufficient to demonstrate workability. King Instrument Corp. v. Otari Corp., 767 F.2d 853, 860, 226 USPQ 402, 407 (Fed. Cir. 1985).
For additional cases pertaining to the requirements necessary to establish actual reduction to practice see DSL Dynamic Sciences, Ltd. v. Union Switch & Signal, Inc., 928 F.2d 1122, 1126, 18 USPQ2d 1152, 1155 (Fed. Cir. 1991) ("events occurring after an alleged actual reduction to practice can call into question whether reduction to practice has in fact occurred"); Fitzgerald v. Arbib, 268 F.2d 763, 765-66, 122 USPQ 530, 531-32 (CCPA 1959) ("the reduction to practice of a three-dimensional design invention requires the production of an article embodying that design" in "other than a mere drawing"); Birmingham v. Randall, 171 F.2d 957, 80 USPQ 371, 372 (CCPA 1948) (To establish an actual reduction to practice of an invention directed to a method of making a product, it is not enough to show that the method was performed. "[S]uch an invention is not reduced to practice until it is established that the product made by the process is satisfactory, and this may require successful testing of the product."). See MPEP 2138.05.
Claim 1 encompasses a genus of mouse. However, the specification doesn't have adequate support in the disclosure to establish a method of a composite any mouse model for simulating exacerbation periodontitis by hyperuricemia.
Teachings of the Specification:
The specification and claim 11 discloses a specific fatty male C57BL/6 mice, 18-22 g, 6-8 weeks old, were provided by the Guangdong Provincial Animal Experiment Center and raised in an SPF-level environment at the Animal Center of Guangdong Huawei Testing Co., Ltd. The 5-0 nonabsorbable braided silk thread was provided by Johnson & Johnson, model Ethicon Mousse SA82G. Micro-CT was provided by Bruker Company of Germany, the model number was skyscanll 72. Potassium oxonate (PO), sodium carboxymethylcellulose (CMC-Na), and allopurinol (Allo) were provided by Sigma Company, and their model numbers were 156124-25G, C5678-500G andA8003-25G respectively ([0080], [0027]. Therefore, skilled in the art can prepare composite mouse model for simulating exacerbation periodontitis by hyperuricemia with the specific male C57BL/6 mouse as disclosed in specification and claim 11. However, specification does not disclose any mouse to prepare the composite model for simulating exacerbation periodontitis by hyperuricemia. Therefore, the specification fails to identify any mouse to prepare the hyperuricemia model.
Working examples of the specification:
Applicant discloses 50 male C57BL/6 mice [0092] were randomly divided into Nue, NuP, Hue, HuP, and HuP + Allo groups [0093] with 10 mice in each group. Mice in the Nue and NuP groups were intraperitoneally injected with 0.5% CMC-Na at a fixed frequency once a day (the injection volume was consistent with the PO volume required for mice under the same weight) for 28 consecutive days. The mice in the NuP group were ligated with 5-0 silk sutures on bilateral maxillary second molars by a microneedle holder on the 7th day [0094]. Any embodiments that meet all the limitations of the claim are reduced to practice, and the specification does not show or disclose that any mouse to prepare the hyperuricemia model. Therefore, an actual reduction to practice of an invention directed to any mouse to prepare the composite model for simulating exacerbation periodontitis by hyperuricemia of instant methos is not established at the time of filling and POSITA cannot predictably identify hyperuricemia mouse model that exercise the instant invention of any mouse to prepare the composite model. Accordingly, the successful testing of the method of the current invention is not shows reduced to practice, therefore, it is not established that the product is satisfactory. See MPEP 2163(I)-(II) and 2163.02.
MPEP § 2163, besides an actual reduction to practice, Applicant may prove possession of the claimed invention by a showing that the invention was “ready for patenting” such as by the disclosure of drawings or structural chemical formulas that show that the invention was complete, or by describing distinguishing identifying characteristics sufficient to show that the Applicant was in possession of the claimed invention. Further, as per MPEP § 2163, “[f]or some arts, there is an inverse correlation between the level of skill and knowledge in the art and the specificity of disclosure necessary to satisfy the written description requirement.”
State of the Art at the Time of Filing:
The teaching of Chen et al. (CN108030784A; cited in IDS filed 04/18/2025; see attached Google patent English translation; hereinafter “Chen”) a method for establishing a stable hyperuricemia model in a short time by combining fructose with potassium oxonate comprises the steps: select male clean-grade Sprague–Dawley (SD) rats with a body weight of 180-220g and an age of 6-8 weeks, and raise them in a clean-grade or SPF-grade animal breeding room; then rats were given 10% fructose drinking water uninterruptedly for 24 hours in an SPF animal breeding room, and injected intraperitoneally at room temperature 500 mg·kg -1 of uricase inhibitor oxonate potassium was administered. The model was established continuously according to the administration to the rats every day, and the administration continued for 3 weeks (see p. 2 “Contents of the invention” ¶). Separately, Hickman et al. (Principles of Animal Research for Graduate and Undergraduate Students, 117–175, 2016, cited in PTO892, hereinafter “Hickman”) discloses mouse fanciers around the turn of the 20th century are the source of the majority of the laboratory mice that are in use today. A summary of the overarching categories of mouse models that are available is presented in Table 7.1. Hicman further indicates the aggressive of mice depends on strains, the more aggressive strains are BALB/c, C57BL/10, C57BL/6, DBA/2, and outbred Swiss. Therefore, it is obvious that any mouse can prepare the composite model for simulating exacerbation periodontitis by hyperuricemia. Therefore, it is obvious that prior art does not support identifying any mouse to prepare the hyperuricemia model.
The quantity of experimentation needed to make or use the invention:
Applicants have claimed a genus of any mouse to prepare the hyperuricemia model however, SPEC is only indicating the use of fatty male C57BL/6 mice, 18-22 g, 6-8 weeks old (Fig. 1A filed 01/17/2025). The genus of any mouse to prepare the hyperuricemia model with instant method claimed by Applicant cannot be predictably made or used by the ordinary artisan. Such random experimentation to identify any mouse and is embraced by Applicant's claims requires undue experimentation. Furthermore, functionally defined genus claims can be inherently vulnerable to invalidity challenges for lack of written description support, especially in technology fields that are highly unpredictable, where it is difficult to establish a correlation between structure and function for the whole genus or to predict what would be covered by the functionally claimed genus.
See ABBVIE DEUTSCHLAND GMBH & 2 CO. v. JANSSEN BIOTECH, INC., Appeals from the United States District Court for the District of Massachusetts in Nos. 09-CV-11340-FDS, 10-CV-40003-FDS, and 10-CV-40004-FDS, Judge F. Dennis Saylor, IV. See also Ariad, 598 F.3d at 1351 ("[T]he level of detail required to satisfy the written description requirement varies depending on the nature and scope of the claims and on the complexity and predictability of the relevant technology.”); see also Centocor Ortho Biotech, Inc. v. Abbott Labs., 636 F.3d 1341, 1352 (Fed. Cir. 2011) (noting the technical challenges in developing fully human antibodies of a known human protein).
Conclusion:
With these additional evidence, the nucleic acid sequence comprising any mouse to prepare the hyperuricemia model is not well established at the time of filling and the ordinary artisan cannot predictably identify any in a method. Therefore, one of skill in the art would neither expect nor predict the nucleic acid sequence comprising any mouse to prepare the hyperuricemia model.
Therefore, it concludes that the claimed genus of any mouse to prepare the hyperuricemia model doesn't have an adequate written description. It concludes that a skilled artisan would find the specification inadequately described. Accordingly, the Applicant did not sufficiently possess the broader invention as claimed in claim 1 and dependent claims 2-10 and 12.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(B) CONCLUSION. —The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claim 10 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
MPEP 2173.05(u) states that the presence of a trademark or trade name in a claim is not, per se, improper under 35 U.S.C. 112(b) or pre-AIA 35 U.S.C. 112, second paragraph, but the claim should be carefully analyzed to determine how the mark or name is used in the claim. It is important to recognize that a trademark or trade name is used to identify a source of goods and is not the name of the goods themselves. Thus, a trademark or trade name does not define or describe the goods associated with the trademark or trade name. See definitions of trademark and trade name in MPEP § 608.01(v)
Claim 10 recited the microneedle holder is W40350, however, the specification does not define “W40350,” or identify the manufacturer or source associated with this designation, or provide structural or functional characteristics sufficient to identify what constitutes a “W40350” microneedle holder. Accordingly, it is unclear from claim and specification what functional limitation are imparted to the claimed microneedle holder by designation ““W40350”.” POSTA therefore would not be able to predict with reasonable certainty the meets and bounds of the claimed microneedle holder. Furthermore, the Trademark search report of “W40350,” does not identify such particular commercially available product. Therefore, W40350 does not define the structure or functional characteristics of the product. Accordingly, claim 10 is indefinite. Appropriate clarification is required.
Claim Rejections – 35 U.S.C. 101
35 U.S.C. 101 reads as follows:
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
Claim 13 is rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example Ex parte Dunki, 153 USPQ 678 (Bd.App. 1967) and Clinical Products, Ltd. v. Brenner, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966). See MPEP 2173.05(q).
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(B) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claim 13 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention.
Claim 13 recited the use of composite mouse model, however, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced. See MPEP 2173.05(q).
Subject Matter Free of Art
Regarding claims 1-9 and 11-12, Chen et al. (CN108030784A; cited in IDS filed 04/18/2025; hereinafter “Chen”) teaches a method for establishing a stable hyperuricemia model in a short time by combining fructose with potassium oxonate comprises the steps: select male clean-grade Sprague–Dawley (SD) rats with a body weight of 180-220g and an age of 6-8 weeks, and raise them in a clean-grade or SPF-grade animal breeding room; then rats were given 10% fructose drinking water uninterruptedly for 24 hours in an SPF animal breeding room, and injected intraperitoneally at room temperature 500 mg·kg -1 of uricase inhibitor oxonate potassium was administered. The model was established continuously according to the administration to the rats every day, and the administration continued for 3 weeks (see p. 2 “Contents of the invention” ¶). Hower Chen does not teaches or reasonably suggest to continuously injecting potassium oxonate into the abdominal cavity of the mouse for seven days to establish hyperuricemia; on the 7th day, using a micro-needle holder to ligate the maxillary second molar of the mouse with a surgical silk suture to establish a periodontitis model; and continuing to continuously inject potassium oxonate into the abdominal cavity of the mouse for another seven days to establish a composite mouse model for simulating hyperuricemia-aggravated periodontitis.
Conclusion
No claims are allowed.
Examiner Contact Information
Any inquiry concerning this communication or earlier communications from the examiner should be directed to MASUDUR RAHMAN whose telephone number is 571-272-0196. The examiner can normally be reached M-F 8-5 (EST).
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Christopher Babic can be reached on (571) 272-8507. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/MASUDUR RAHMAN/ Patent Examiner, Art Unit 1633
/JEREMY C FLINDERS/ Primary Examiner, Art Unit 1684